Chemocentryx, inc. (CCXI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenue:
Collaboration and license revenue from related party

35,952

42,875

82,497

11,435

-

-

6,060

5,419

31,673

34,861

Grant revenue

176

0

0

500

-

-

-

-

-

-

Total revenue

36,128

42,875

82,497

11,935

-

-

-

-

-

-

Operating expenses:
Research and development

70,276

62,736

49,495

37,945

33,183

33,815

33,541

34,569

28,359

33,527

General and administrative

24,155

20,409

16,509

14,710

14,506

13,584

11,634

10,480

7,615

7,292

Total operating expenses

94,431

83,145

66,004

52,655

47,689

47,399

45,175

45,049

35,974

40,819

Loss from operations

-58,303

-40,270

16,493

-40,720

-47,689

-47,399

-39,115

-39,630

-4,301

-5,958

Other income (expense):
Interest income

4,963

3,528

1,370

757

384

494

501

533

402

436

Interest expense

2,149

1,224

4

-

-

24

59

794

734

81

Other income

-

-

-

-

-

-

-

-

16

2,434

Total other income, net

2,814

2,304

1,366

757

384

470

442

-261

-316

-

Loss before provision for income taxes

-

-

-

-

-

-

-

-

-

-3,169

Income tax benefit

-

-

-

-

-

-

-

-

-

-73

Net loss

-55,489

-37,966

17,859

-39,963

-47,305

-46,929

-38,673

-39,891

-4,617

-3,096

Net (loss) income per common share
Basic

-0.98

-0.76

0.37

-0.86

-1.08

-

-

-

-

-

Diluted

-0.98

-0.76

0.36

-0.86

-1.08

-

-

-

-

-

Shares used to compute net (loss) income per common share
Basic

56,898

49,814

48,413

46,432

43

-

-

-

-

-

Diluted

56,898

49,814

49,615

46,432

43

-

-

-

-

-

Basic and diluted net loss per common share

-

-

-

-

-

-1.08

-0.95

-1.13

-1.10

-0.76

Shares used to compute basic and diluted net loss per common share

-

-

-

-

-

43

40

35,407

4

4,081